June 17 (Reuters) - CanSino Biologics Inc :
* UNIT RECEIVED PRODUCT REGISTRATION CONDITIONAL APPROVAL FOR CONVIDECIA RECOMBINANT NOVEL CORONAVIRUS VACCINE FOR EMERGANCY USE
Source text for Eikon: Further company coverage:
(Reuters.briefs@thomsonreuters.com)
精彩评论